Sales momentum accelerated significantly in Q3 led by broad-based growth across the ophthalmology segment, particularly in Asia. Growth in adjusted EBIT was even higher on the back of the increasing proportion of high margin recurring revenue in the total sales mix. Post the robust show ytd, FY18/19 sales and profitability guidance has been raised. Nonetheless, given the planned investments into R&D in the next year, we foresee limited margin expansion in FY19/20.